BRAF and acute myeloid leukemia: Coinciding with BRAF, ALK has been considered as a driving event in several cancer types due to its mutation and amplification, while the expression of ALK in AML samples and high-risk group is contrarily elevated, making it a risk factor to indicate oncogenesis and poor prognostic.